What happened with VJET today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Catheter Precision, Inc., since renamed Flyte Aviation, Inc., primarily serves hospitals that perform procedures to diagnose and treat heart-rhythm disorders. Most revenue comes from VIVO and LockeT. VIVO combines patient images and electrical recordings into a three-dimensional heart map to help doctors locate the source of certain abnormal ventricular rhythms before a procedure, in patients without structural heart disease. Each use requires disposable VIVO Positioning Patches. LockeT holds closure sutures temporarily and spreads their tension to help stop bleeding and make the sutures easier to remove.
Hospitals buy through the company’s salespeople or, internationally, through direct sales and distributors. Demonstrations, staff training and support during procedures help hospitals adopt the products. Revenue depends heavily on a small group of customers. Demand also depends on hospitals recovering device costs through payments for procedures, rather than separate reimbursement for the products. Existing regulatory clearances restrict the uses the company can promote; expanding VIVO to patients with ischemic heart disease requires additional U.S. clearance.
The company also operates FLYTE under a holding-company structure while continuing its life-sciences business. It views the private aviation charter business as a way to attract capital to help fund operating losses. Its medical-product revenue does not yet cover operating needs, so it remains dependent on additional financing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Catheter Precision’s medical-device results hinge on hospitals adopting LockeT and VIVO against competitors including Biosense-Webster (J&J), while its new FLYTE charter business adds separate aviation exposure.
Haemonetics competes directly for hospitals’ purchases of devices that close catheter access sites: its VASCADE rivals Catheter Precision’s LockeT suture-retention device. Watch VASCADE adoption in its Hospital business for signs of the competition facing LockeT’s initial and repeat hospital orders.
Abbott Laboratories competes with Catheter Precision for hospitals’ heart-rhythm procedure equipment purchases, and its Perclose directly rivals the LockeT device that holds closure sutures in place. Watch Perclose adoption for competitive pressure on LockeT, whose sales growth has depended on initial and repeat hospital orders.
Boston Scientific sells heart-rhythm procedure devices to the same hospital labs that buy Catheter Precision’s VIVO mapping system and LockeT closure-suture device. Watch its electrophysiology offering: broader product bundles and discounts are a competitive challenge for Catheter Precision in those labs.
Medtronic competes for the hospital heart-rhythm customers that buy Catheter Precision’s VIVO mapping system and LockeT suture-retention device, selling cardiac devices and lab technologies. Its new cardiac products are worth watching for the alternatives hospitals have when choosing procedure equipment.
Adagio Medical Holdings, Inc develops catheter systems that freeze tissue to treat ventricular tachycardia, while Catheter Precision sells hospitals VIVO to locate idiopathic ventricular arrhythmias before procedures in patients with structurally normal hearts. Watch Adagio’s vCLAS clinical and U.S. approval milestones as signals of treatment development in this field, not evidence of VIVO orders.
Abbott Laboratories earningsABT
Abbott's report will show whether hospitals are adopting Perclose, a direct rival to Flyte Aviation's LockeT for closure-suture purchases.
Look for Abbott's disclosures on Perclose adoption and sales of related heart-rhythm equipment in hospitals. Stronger Perclose adoption would mean tougher competition when hospitals choose a suture-retention device; limited adoption would offer less evidence that Perclose is crowding out LockeT's initial and repeat orders. Abbott's results describe a competitor, not Flyte Aviation's own orders.
Fed Interest Rate Decision
For Catheter Precision, the Fed’s policy rate shapes the cost and availability of borrowing as the company seeks financing to fund operations and repay debt.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, borrowing may become more costly and harder to secure, adding pressure to fund operations and meet debt obligations.
If it comes in below expectations
If the policy rate is lower than expected, borrowing may become cheaper and easier to secure, potentially easing the company’s financing pressure.
Flyte Aviation, Inc. earningsThis company
Flyte Aviation's report will show whether hospitals keep ordering LockeT, whether VIVO sales hold up, and how much product revenue supports the business.
Read LockeT sales and repeat orders alongside VIVO system sales. Continued LockeT orders with steady VIVO sales would point to broader hospital adoption; if growth rests on a few LockeT orders while VIVO weakens, commercial traction remains fragile. Then check cash and financing disclosures: adequate funding gives the company time to build hospital sales, while a shortfall could constrain selling and product development.
